Ascendis Pharma A/S
ASND
$223.82
-$3.59-1.58%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -39.07M | -71.30M | -44.10M | -99.58M | -41.01M |
| Total Depreciation and Amortization | 5.05M | 4.70M | 4.89M | 4.78M | 4.27M |
| Total Amortization of Deferred Charges | 570.40K | -- | -- | -- | 497.80K |
| Total Other Non-Cash Items | 72.50M | 40.31M | 80.55M | 26.88M | 65.20M |
| Change in Net Operating Assets | 46.40M | 28.81M | -49.67M | 52.86M | -121.89M |
| Cash from Operations | 85.44M | 2.52M | -8.33M | -15.06M | -92.93M |
| Capital Expenditure | -3.95M | -62.00K | -4.92M | -739.80K | -408.30K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -1.10K |
| Cash from Investing | -3.95M | -62.00K | -4.92M | -739.80K | -409.30K |
| Total Debt Issued | -- | -- | -- | -- | 0.00 |
| Total Debt Repaid | -6.83M | -6.57M | -5.49M | -3.07M | -2.95M |
| Issuance of Common Stock | 15.35M | 45.43M | 12.47M | 13.83M | 22.33M |
| Repurchase of Common Stock | 0.00 | 0.00 | 0.00 | -28.79M | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -19.29M |
| Cash from Financing | 9.91M | 45.42M | 7.92M | -18.97M | 92.70K |
| Foreign Exchange rate Adjustments | -1.83M | 4.78M | -21.77M | -9.03M | 22.92M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 89.58M | 52.66M | -27.10M | -43.80M | -70.32M |